NCT04444856View on ClinicalTrials.gov

Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern

CompletedOBSERVATIONAL
Enrollment

225

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

January 13, 2021

Study Completion Date

January 13, 2021

Conditions
Severe Postpartum Haemorrhage
Interventions
DRUG

Eptacog alfa (activated)

The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.

OTHER

Standard of care

The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.

Trial Locations (1)

CH-3010

Novo Nordisk Investigational Site, Bern

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY